Kyverna Therapeutics(NASDAQ) KYTX

Kyverna Therapeutics, Inc. makes cell therapies for serious autoimmune diseases. These treatments aim to reset the immune system for better health. The company helps patients who suffer from debilitating neurological conditions.

How Kyverna Aims to Heal

• Miv-cel (KYV-101): Autologous chimeric antigen receptor (CAR) T-cell therapy candidate that uses a patient's own modified immune cells to target neurological diseases.
• KYV-102: Proprietary version of the lead therapy candidate that uses a rapid manufacturing process involving whole blood; cleared for clinical study in January 2026.
• KYV-201: Allogeneic CAR T-cell candidate that utilizes donor immune cells; being developed through a research partnership with Intellia Therapeutics.

Recent Strategic Milestones

• Initiated a rolling Biologics License Application for stiff person syndrome in the second quarter of 2026.
• Signed a manufacturing agreement with ElevateBio BaseCamp for clinical and commercial supply on July 23, 2026.
• Obtained Regenerative Medicine Advanced Therapy designation for a multiple sclerosis candidate in August 2026.
• Secured a $150 million senior loan facility from Oxford Finance on Oct. 31, 2025.
• Raised $98.7 million in net proceeds through an underwritten public offering in December 2025.

What Sets the Science Apart

Kyverna uses chimeric antigen receptor technology licensed from the National Institutes of Health to modify a patient's own immune cells. This method aims to reset the immune system by removing B-cells that drive chronic neurological and autoimmune diseases.

Measuring the Financial Path

• Net loss was $78.0 million for the six months ended June 30, 2026, a 10% decrease from the same period in 2025.
• Research and development expenses reached $54.9 million for the six months ended June 30, 2026, down 25% year over year.
• Cash, cash equivalents, and marketable securities totaled $199.4 million as of June 30, 2026.
• Market capitalization stood at $542.6 million for the second quarter of 2026, up 308.9% year over year.
• Price-to-earnings ratio was -3.5 for the second quarter of 2026.

Bottom Line

Kyverna has transitioned from an early research firm into a late-stage developer focused on severe autoimmune conditions. Its progress in manufacturing partnerships and regulatory filings supports its shift toward potential commercial operations.